Literature DB >> 34295441

Immune System Effects on Breast Cancer.

Jensen N Amens1, Gökhan Bahçecioglu1, Pinar Zorlutuna1,2,3,4.   

Abstract

Breast cancer is one of the most common cancers in women, with the ability to metastasize to secondary organs, which is the main cause of cancer-related deaths. Understanding how breast tumors progress is essential for developing better treatment strategies against breast cancer. Until recently, it has been considered that breast cancer elicits a small immune response. However, it is now clear that breast tumor progression is either prevented by the action of antitumor immunity or exacerbated by proinflammatory cytokines released mainly by the immune cells. In this comprehensive review we first explain antitumor immunity, then continue with how the tumor suppresses and evades the immune response, and next, outline the role of inflammation in breast tumor initiation and progression. We finally review the current immunotherapeutic and immunoengineering strategies against breast cancer as a promising emerging approach for the discovery and design of immune system-based strategies for breast cancer treatment. © Biomedical Engineering Society 2021.

Entities:  

Keywords:  Antitumor immunity; Breast cancer progression; Immune cells; Immune evasion; Immune suppression; Immunotherapy; Proinflammatory cytokines; immune engineering

Year:  2021        PMID: 34295441      PMCID: PMC8280260          DOI: 10.1007/s12195-021-00679-8

Source DB:  PubMed          Journal:  Cell Mol Bioeng        ISSN: 1865-5025            Impact factor:   3.337


  115 in total

1.  A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation.

Authors:  Arnaud Foussat; Françoise Cottrez; Valérie Brun; Nathalie Fournier; Jean-Philippe Breittmayer; Hervé Groux
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.

Authors:  Hyung W Lim; Peter Hillsamer; Allison H Banham; Chang H Kim
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

Review 3.  Breast Cancer Immunotherapy: Facts and Hopes.

Authors:  Leisha A Emens
Journal:  Clin Cancer Res       Date:  2017-08-11       Impact factor: 12.531

4.  CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer.

Authors:  Gong-Ling Peng; Liang Li; Ya-Wen Guo; Pan Yu; Xing-Jie Yin; Shan Wang; Chun-Ping Liu
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

5.  Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression.

Authors:  Giulia Escobar; Davide Moi; Anna Ranghetti; Pinar Ozkal-Baydin; Mario Leonardo Squadrito; Anna Kajaste-Rudnitski; Attilio Bondanza; Bernhard Gentner; Michele De Palma; Roberta Mazzieri; Luigi Naldini
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

6.  Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity.

Authors:  S Ben-Eliyahu; G G Page; R Yirmiya; G Shakhar
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

Review 7.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

8.  Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Authors:  A D Gritzapis; A Mamalaki; A Kretsovali; J Papamatheakis; M Belimezi; S A Perez; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 9.  TNF: a master switch for inflammation to cancer.

Authors:  Gautam Sethi; Bokyung Sung; Bharat B Aggarwal
Journal:  Front Biosci       Date:  2008-05-01

10.  Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner.

Authors:  Lauren W Collison; Meenu R Pillai; Vandana Chaturvedi; Dario A A Vignali
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more
  2 in total

1.  Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.

Authors:  Kevin J Thompson; Roberto A Leon-Ferre; Jason P Sinnwell; David M Zahrieh; Vera J Suman; Filho Otto Metzger; Sarah Asad; Daniel G Stover; Lisa Carey; William M Sikov; James N Ingle; Minetta C Liu; Jodi M Carter; Eric W Klee; Richard M Weinshilboum; Judy C Boughey; Liewei Wang; Fergus J Couch; Matthew P Goetz; Krishna R Kalari
Journal:  NAR Cancer       Date:  2022-06-17

2.  Plg-RKT Expression in Human Breast Cancer Tissues.

Authors:  Lindsey A Miles; Stan Krajewski; Nagyung Baik; Robert J Parmer; Barbara M Mueller
Journal:  Biomolecules       Date:  2022-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.